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Abstract
Introduction Estrogen receptors (ERs) play key roles in breast
cancer development and influence treatment outcome in breast
cancer patients. Identification of molecules that regulate ER
function may facilitate development of breast cancer treatment
strategies. The forkhead box class O (FOXO) transcription
factor FOXO3a has been suggested to function as a tumor
suppressor in breast cancer. Using protein-protein interaction
screening, we found that FOXO3a interacted with ER-α and ER-
β proteins in the human breast carcinoma cell line MCF-7,
suggesting that there exists a crosstalk between the FOXO3a
and ER signaling pathways in estrogen-dependent breast
cancer cells.
Methods The interaction between FOXO3a and ER was
investigated by using co-immunoprecipitation and
immunoblotting assays. Inhibition of ER-α and ER-β
transactivation activity by FOXO was determined by luciferase
reporter assays. Cell proliferation in culture was evaluated by
counting cell numbers. Tumorigenesis was assessed in athymic
mice that were injected with MCF-7 cell lines over-expressing
FOXO3a. Protein expression levels of cyclin-dependent kinase
inhibitors, cyclins, ERs, FOXM1, and the proteins encoded by
ER-regulated genes in MCF-7 cell lines and breast tumors were
examined by immunoblotting analysis and immunohistochemical
staining.
Results We found that FOXO3a interacted with ER-α and ER-
β proteins and inhibited 17β-estradiol (E2)-dependent, ER-
regulated transcriptional activities. Consistent with these
observations, expression of FOXO3a in the ER-positive MCF-7
cells decreased the expression of several ER-regulated genes,
some of which play important roles in cell proliferation.
Moreover, we found that FOXO3a upregulated the expression
of the cyclin-dependent kinase inhibitors p21Cip1, p27Kip1,
and p57Kip2. These findings suggest that FOXO3a induces cell
growth arrest to effect tumor suppression. FOXO3a repressed
the growth and survival of MCF-7 cells in cell culture. In an
orthotopic breast cancer xenograft model in athymic mice, over-
expression of FOXO3a in MCF-7 cells suppressed their E2-
induced tumorigenesis, whereas knockdown of FOXO3a in
MCF-7 resulted in the E2-independent growth.
Conclusion Functional interaction between FOXO3a and ER
plays a critical role in suppressing estrogen-dependent breast
cancer cell growth and tumorigenesis in vivo. This suggests that
agents that activate FOXO3a may be novel therapeutic agents
that can inhibit and prevent tumor proliferation and development
in breast cancer.
CDK = cyclin-dependent kinase; E2 = 17β-estradiol; ER = estrogen receptor; ERE = ER-responsive element; FasL = Fas ligand; FasR = Fas receptor; 
FOXO = forkhead box class O; FOXM1 = forkhead box M1; HA = hemagglutinin; IKK = IκB kinase; luc = luciferase reporter; PBS = phosphate-
buffered saline; PgR = progesterone receptor.Breast Cancer Research    Vol 10 No 1    Zou et al.
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Introduction
Breast cancer is the most common malignancy diagnosed
among women worldwide, and it is the second leading cause
of cancer death [1]. Approximately 70% of human breast can-
cers express estrogen receptors (ERs) [2-4]. Many ER-α-pos-
itive human breast cancer cells require estrogen for
proliferation and undergo apoptotic cell death when they are
deprived of it [5]. Clinically, the presence of ER-α in breast
cancer is viewed as a good prognostic factor, being associ-
ated with a lower risk for relapse and better overall disease-
free survival [6]. Indeed, ER-α is a major target for endocrine
therapy [7], and functional ER-α protein is both sufficient and
necessary to predict responsiveness to such therapy in a high
proportion of breast tumors. Thus, assessment of ER status
has become standard practice in the clinical management of
breast cancer [8,9], with hormonal intervention offered to
patients with ER-α-positive tumors.
Current endocrine therapies for ER-α-positive breast cancer
target the action of estrogen on breast cancer cells by using
selective ER modulators such as tamoxifen [7,10], aromatase
inhibitors such as exemestane [11], or pure antiestrogens
such as fulvestrant [12]. However, only about 50% of ER-pos-
itive tumors respond to currently available hormonal therapies,
and most tumors that initially respond eventually become
resistant to endocrine therapy, even though ER may still be
present in the tumor tissue [13]. Attempts to prevent or
reverse antiestrogen resistance have been hampered by the
lack of knowledge of the signaling mechanisms that underlie
the regulation of ER function.
The cellular and molecular events that regulate ER-α and ER-
β protein expression and function are poorly understood.
Expression of ER-α may not be regulated genetically; for exam-
ple, lack of expression of ER-α generally is not associated with
physical loss of the ER-α gene [14]. However, ER-α expres-
sion can be regulated through epigenetic modification, for
instance methylation at the promoter [15], by post-transla-
tional modifications, or through direct interaction with core-
pressor proteins that repress ER-α-mediated transcriptional
activity [16,17]. Less is known of the regulation of expression
and function of ER-β in breast cancer cells and tissues. Addi-
tional information on the cellular and molecular events that reg-
ulate ER-α and ER-β protein expression and function is
needed.
FOXO3a, which is one of the forkhead box class O (FOXO)
transcription factors, is a key tumor suppressor in breast can-
cer [18]. The function of FOXO3a is regulated mainly by
nuclear translocation. In general, FOXO factors in animal cells
are regulated by Akt or other kinases, which phosphorylate
them at conserved serine/threonine residues [18-20]. This
phosphorylation leads to the release of the FOXO transcrip-
tion factors from the DNA and translocation of those factors to
the cytoplasm, where 14-3-3 protein binds to the phosphor-
ylated FOXO factors and retains them as inactive proteins in
the cytoplasm. However, in the absence of stimulation from
survival signals, Akt is inactivated in quiescent cells, which
results in retention of FOXO factors in the nucleus. In addition
to Akt, IκB kinase (IKK)-β is also important in regulating
FOXO3a localization [18,21].
Nuclear FOXO has been shown to upregulate the expression
of specific target genes that modulate the cell metabolic state
or oxidative stress or aging [18-23], those that control cell
cycle progression such as cyclin-dependent kinase (CDK)
inhibitors [18,24-26], or those that regulate the mitotic pro-
gram such as cyclin B and Polo-like kinase [18,26]. Downreg-
ulation of cyclin D has been implicated in FOXO-induced cell
cycle inhibition in some cancer cell lines [27]. Nuclear FOXO
has also been reported to induce cellular apoptosis through
upregulation of Fas ligand (Fas-L) [28], Bim [29-31], and
tumor necrosis factor-related apoptosis inducing ligand
[32,33]. Changes in FOXO function could tip the balance
between cellular differentiation and neoplastic transformation
[18-20].
Although FOXO3a reportedly can suppress cell growth and
tumorigenesis in ER-negative breast cancer cells [18,21],
whether FOXO3a also regulates cell proliferation or tumori-
genesis in ER-positive breast tumors is unknown. Here we
report our discovery that FOXO3a interacts with ERs. We
found that FOXO3a interacts with both ER-α and ER-β and
inhibits their transcriptional activities. Gene expression profil-
ing with a DNA microarray suggested that FOXO3a inhibits
the expression of ER target genes. FOXO3a suppressed pro-
liferation of MCF-7 breast cancer cells by inducing the expres-
sion of key CDK inhibitors and reducing the expression of
cyclin D1. Moreover, FOXO3a suppressed tumorigenesis of
E2-induced tumorigenesis of MCF-7 cells in an animal ortho-
topic breast tumor model, suggesting that FOXO3a plays a
critical tumor-suppression role in estrogen-dependent breast
cancer.
Materials and methods
Cell culture and cell lines
Cells were cultured in Dulbecco's modified Eagle's medium/
F12 medium supplemented with 10% or 5% fetal bovine
serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA) or
phenol red-free Dulbecco's modified Eagle's medium/F12
medium supplemented with 5% charcoal-stripped fetal bovine
serum (Atlanta Biologicals, Lawrenceville, GA), with or without
100 nmol/l 17β-estradiol (E2; Sigma-Aldrich, St. Louis, MO,
USA). A MCF-7 and 293T cells were obtained from the Amer-
ican Type Culture Collection (Rockville, MA, USA). MCF-7 sta-
ble cell lines over-expressing FOXO3a (MCF7-FO) were
generated by retroviral transduction with the pBabe vector
containing hemagglutinin (HA)-tagged FOXO3a cDNA under
the transcriptional control of the murine leukemia virus long ter-
minal repeat [34] and a puromycin-resistant gene. This pBabe-Available online http://breast-cancer-research.com/content/10/1/R21
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HA-FOXO3a construct was created by ligating a BamHI-XhoI
fragment of HA-FOXO3a into a pBabe-puro vector cut with
BamHI and SalI. MCF-7 control (MCF7-C) cell lines were
established with retroviruses containing the pBabe vector
without a cDNA insert. After puromycin selection (0.2 to 1.0
μg/ml), MCF7-FO pooled clones (MCF7-FO) and individual
clones (FO10, FO33, and FO41), vector control pooled
clones (MCF7-C,) and individual clones (C4, C5, and C12)
were selected. MCF-7 stable cell line with FOXO3a downreg-
ulated (MCF7-d8_pa) was generated by retroviral transduc-
tion with a retroviral construct containing small-hairpin RNA
interference targeting FOXO3a (V2HS_169297; Open Bio-
systems, Huntsville, AL, USA). After puromycin selection (0.2
to 1.0 μg/ml), MCF7-knockdown pooled clones (MCF7-
d8_pa) were selected.
Antibodies
Antibodies against FOXO3a (FKHRL1, sc-11351), cyclin D1,
complement C3, and β-tubulin were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies
against cathepsin D, progesterone receptor (PgR), and pS2
were purchased from Novocastra Laboratories (Newcastle
Upon Tyne, UK). Antibodies against p27Kip1, p21Cip1,
p57Kip2, and cyclin E were obtained from BD Biosciences
(San Jose, CA, USA). Antibodies against ER-α and ER-β were
purchased from Upstate USA (Charlottesville, VA, USA).
Finally, antibodies against HA and β-actin were purchased
from Roche Applied Science (Indianapolis, IN, USA) and
Sigma (St. Louis, MO, USA), respectively.
Antibody array and DNA microarray
Protein-protein interactions were screened using an Antibod-
yArray from Hypromatrix, Inc. (Worcester, MA, USA). The array
was incubated with whole-cell lysates of MCF7-FO33 cells,
followed by a horseradish peroxidase-conjugated anti-HA
monoclonal antibody, in accordance with the manufacturer's
instructions. Proteins were then visualized using an enhanced
chemiluminescence visualization kit from Santa Cruz Biotech-
nology. Of several positive antibody candidates on the mem-
brane of the AntibodyArray, we identified a positive signal at
the spot that was immobilized with an antibody against ER-α.
Immunoprecipitation and immunoblotting
These experiments were conducted as described previously
[21] with some modifications. Briefly, cells were washed twice
with phosphate-buffered saline (PBS) and lysed with lysis
buffer at 4°C for 20 minutes. After being sonicated with an
ultrasound sonicator, whole lysates were centrifuged at
16,000 g for 10 minutes to remove cell debris. Total protein
concentration was determined using a Bio-Rad kit (Hercules,
CA, USA) using bovine serum albumin as a standard. Samples
were first precleared with a nonspecific IgG control. Pre-
cleared lysates were then incubated with a specific antibody
and rotated at 4°C overnight followed by the addition of 25 μl
of 50% protein A- or protein G-sepharose slurry with rotation
for 1 hour. Protein A or protein G beads were collected and
washed with lysis buffer four times. Immunoprecipitation sam-
ples were resolved by SDS-PAGE and analyzed by immunob-
lotting. The protein samples were subjected to SDS-PAGE
and transferred onto nitrocellulose or polyvinylidene difluoride
membranes. The membranes were blocked with 5% nonfat dry
milk or bovine serum albumin in PBS containing 0.05% Tween
20 and incubated with primary antibodies and then with horse-
radish peroxidase-conjugated secondary antibodies, in
accordance with the manufacturer's instructions. The immuno-
blots were visualized using an enhanced chemiluminescence
visualization kit (Santa Cruz Biotechnology).
DNA transfection and cell proliferation assay
Transient DNA transfection of MCF-7 or 293T cells was per-
formed as described previously [21,31] with the DNAs or with
an optimal ratio of DNA mixtures containing 0.1 μg ER-respon-
sive element (ERE)-luc (luciferase reporter), 0.3 μg ER-α or
ER-β, 0.9 μg HA-FOXO3a or Flag-FOXO1a, 5.4 μg IKK-β [21]
or control vector, and 0.01 μg pRL-TK (Promega, Madison,
WI, USA), plus Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). Cell proliferation was measured by trypan blue staining
and direct cell counting.
Tumorigenesis and growth of breast tumors in vivo
To determine tumorigenicity and establish orthotopic breast
cancer animal models, female athymic (nu/nu) nude mice were
purchased from the NCI Frederick Cancer Research Center
(Frederick, MD, USA) and maintained aseptically in an athymic
animal room. A 0.72 mg E2 60-day release pellet (Innovative
Research of America, Sarasota, FL, USA) was implanted sub-
cutaneously on the dorsal side of each mouse 1 day before
tumor cell implantation to support the growth of the estrogen-
dependent MCF-7 cell derived tumors [35]. For tumor cell
implantation, MCF7-FO or control (MCF7-C) cells in log-
phase growth were harvested, washed with PBS, and resus-
pended in PBS. Then 2 × 106 cells in 0.25 ml of the mixture
were injected into the mammary fat pads of female athymic
mice, as described previously [21,35]. Tumors were examined
twice weekly; length, width, and thickness measurements
were obtained with calipers and tumor volumes were calcu-
lated. Data are presented as means and standard deviations of
three experiments with 10 mice in each group. All procedures
were performed in compliance with the guidelines of the Uni-
versity of Texas MD Anderson Cancer Center Institutional Ani-
mal Care and Use Committee and the US National Institutes
of Health.
Immunohistochemical staining
Immunohistochemical staining was performed as described
previously [21]. Breast tumors were excised from MCF-7
tumor bearing mice 35 days after inoculation of the test or con-
trol cells. Five independent tumors (each from a different
mouse) were taken from MCF7-FO33 and MCF7-C5 groups
for testing. Tumor samples were fixed in formalin, sectioned,Breast Cancer Research    Vol 10 No 1    Zou et al.
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placed on slides, and incubated with specific antibodies. Sec-
tions were then treated with biotin-conjugated secondary anti-
body followed by avidin biotin-peroxidase complex and amino-
ethyl carbazole as a chromogen.
Statistical analysis
Data are expressed as means ± standard deviations from at
least three determinations. The statistical significance of differ-
ences in cell proliferation and tumor growth between two
groups was analyzed with two-sided unpaired Student's t-
tests when the variances were equal, or with Welch's cor-
rected t-tests when the variances were unequal, using Graph-
pad statistical software (San Diego, CA, USA). All statistical
tests were two-sided, and P values less than 0.05 were con-
sidered statistically significant.
Results
Identification of FOXO3a as an ER-α-interacting protein
To investigate pathways that are modulated by FOXO3a, we
performed a protein-protein interaction screen using an anti-
body array. We used cell lysates prepared from MCF-7 cells
that were stably transfected with FOXO3a (MCF7-FO) to
probe the antibody array and found that FOXO3a interacted
with ER-α. We then confirmed the interaction between
FOXO3a and ER using co-immunoprecipitation and immuno-
blotting assays. We found that FOXO3a physically interacted
with ER-α and ER-β in the presence of E2 when we analyzed
total lysates of 293T cells co-transfected with either HA-
tagged FOXO3a plus Flag-ER-α or Flag-FOXO3a and HA-
ER-β expression vectors with an anti-HA-specific or anti-Flag
tag-specific antibody (Figure 1). We also used MCF-7 cells
(an ER-positive cell line and requires the presence of E2 for
growth in culture) and antibodies to show that endogenous
FOXO3a associated with ER-α (Figure 2a,b) and ER-β (Figure
2c,d).
FOXO3a interacts with and inhibits the transactivation activity
of ER-α and ER-β We then tested the effect of FOXO3a on
the ER-dependent transcriptional activation of a promoter con-
taining EREs driving a luc gene. Co-transfection of FOXO3a
together with ER-α or ER-β into 293T cells resulted in strong
inhibition of ER-α or ER-β activity. Because IKK-β is known to
inhibit FOXO3a activity potently [21], we cotransfected
FOXO3a and ER-α or ER-β together with IKK-β and found that
IKK-β restored much of the activity of ER-α or ER-β on the
ERE-luc reporter (Figure 3a,b). These findings support the
conclusion that repression of ER-α or ER-β activity on the
ERE-luc reporter takes place specifically through FOXO3a.
We also examined the effect of a different FOXO factor,
namely FOXO1a, on ER-α and ER-β activity using the same
co-transfection approach and found similar results (Figure
3c,d). These findings suggest that FOXO1a can also specifi-
cally inhibit the activity of ER-α or ER-β.
FOXO3a suppresses ER-mediated signaling and 
upregulates CDK inhibitors in MCF-7
To investigate the mechanism by which FOXO3a might regu-
late ER-mediated signaling in breast cancer cells, we used
DNA microarray and compared gene expression profiles of
FOXO3a expressing MCF7-FO33 with the control MCF7-C5
(transfected with an empty vector) cells. The results indicated
the downregulation of expression of certain ER-regulated
genes, including those for PgR, cathepsin D, and complement
C3, in the MCF7-FO33 cells, whereas the expression levels of
ER-α and ER-β seemed unchanged. These findings suggest
that FOXO3a suppresses ER transcriptional activity, perhaps
by acting on ER-α or ER-β protein.
ER-mediated signaling is generally considered critical for the
survival and proliferation of estrogen-dependent breast cancer
cells. To examine the long-term effects of FOXO3a on ER
function in estrogen-dependent breast cancer cells and to elu-
cidate the molecular mechanisms underlying those effects, we
Figure 1
FOXO3a interacts with ER-α and ER-β FOXO3a interacts with ER-α and ER-β. (a) Total lysates of 293T cells 
co-transfected with hemagglutinin (HA)-tagged forkhead box class O 
(FOXO)3a plus Flag-estrogen receptor (ER)-α (lanes 2, 3) or an empty 
vector (lane 1) or an ErbB2 expression vector (lane 4), in the presence 
or absence of 17β-estradiol (E2), were analyzed by immunoprecipita-
tion (IP) with an anti-HA antibody followed by immunoblotting (IB) with 
an anti-Flag tag antibody. (b) The same lysates of 293T cells cotrans-
fected with HA-FOXO3a and Flag-ER-α were subjected to reciprocal 
IP with an anti-Flag (lane 3) or control IgG (IgG; lane 2) or anti-HA 
(positive control, lane 4) followed by IB with an anti-HA. (c) FOXO3a 
associates with ER-β. Total lysates of 293T cells co-transfected with 
the Flag-FOXO3a and HA-ER-β expression vectors in the presence of 
E2 were analyzed by the same IP/IB analysis (IP: control IgG or anti-
Flag [positive control] or anti-HA [lane 3]; IB: anti-Flag). (d) The same 
lysates of 293T cells co-transfected with the Flag-FOXO3a and HA-
ER-β expression vectors were subjected to reciprocal IP with a control 
IgG or anti-Flag (lane 2) or anti-HA (positive control) followed by IB 
with an anti-HA.Available online http://breast-cancer-research.com/content/10/1/R21
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established three MCF7-FO stable cell lines over-expressing
FOXO3a (MCF7-FO10, MCF7-FO33, and MCF7-FO41) and
three control cell lines (MCF7-C4, MCF7-C5, and MCF7-
C12). We then used immunoblotting to investigate whether
constitutive expression of FOXO3a in the MCF7-FO cells
affected FOXO3a transcriptional targets and ER-mediated
signaling. Because p27Kip1 is known to be upregulated by
FOXO3a through a transcriptional control mechanism [18,20]
and CDK inhibitors are known to play important roles in con-
trolling cell cycle and growth, we examined whether three
CDK inhibitors (p27Kip1, p21Cip1, and p57Kip2) were regu-
lated by FOXO3a in MCF7-FO. Interestingly, FOXO3a
induced the expression of three CDK inhibitors in three MCF-
FO cell lines compared with the control (Figure 4). These find-
ings suggest a mechanism by which FOXO3a may induce
breast cancer cell growth arrest through upregulation of all
three key CDK inhibitors, which may be the direct transcrip-
tional targets of FOXO3a.
Although FOXO3a significantly inhibited the expression of cer-
tain ER-regulated genes that are involved in cell growth or sur-
vival (for example, those encoding cathepsin-D, PgR, and
cyclin D1) in the MCF7-FO, it did not alter the expression (Fig-
ure 4) or the cellular localization (data not shown) of ER-α and
ER-β in those cells. In addition, we found that the expression
of cyclin D1 was reduced, but cyclin E (Figure 4) and CDK2
and CDK4 (data not shown) were not significantly different
between MCF7-FO and MCF7-C cells.
Figure 2
FOXO3a associates with endogenous ER-α and ER-β FOXO3a associates with endogenous ER-α and ER-β. (a, b) Forkhead 
box class O (FOXO)3a interacts with endogenous ER-α. Panel a: total 
lysates of MCF-7 cells with 17β-estradiol (E2) were subjected to immu-
noprecipitation (IP) with an anti-FOXO3a (positive control) or negative 
control IgGs (lanes 2 and 3) or anti-estrogen receptor (ER)-α (lane 4), 
followed by immunoblotting (IB) with an anti-FOXO3a antibody. Panel 
b: the same lysates of MCF-7 cells with E2 were subjected to recipro-
cal IP with an anti-FOXO3a antibody (lane 1) or a negative control IgG 
(lanes 2 and 3) or an anti-ER-α (positive control) followed by IB with an 
anti-ER-α. (c, d) FOXO3a interacts with endogenous ER-β. Panel c: 
total lysates of MCF-7 with E2 were subjected to IP/IB (IP: control IgG 
or anti-FOXO3a [positive control] or anti-ER-β (lane 4); IB: anti-
FOXO3a). Panel d: total lysates of MCF-7 with E2 were subjected to a 
reciprocal IP/IB (IP: control IgG or anti-ER-β [positive control] or anti-
FOXO3a [lane 4]; IB: anti-ER-β).
Figure 3
FOXO3a and FOXO1a inhibit the transactivation activities of ER-α and  ER-β FOXO3a and FOXO1a inhibit the transactivation activities of ER-α and 
ER-β. (a, b) 293T cells were co-transfected with estrogen receptor 
(ER)-responsive element (ERE)-luc (firefly luciferase [luc] reporter con-
taining EREs), pRL-TK (renilla luc as a transfection control for normali-
zation), ER-α (panel a) or ER-β (panel b), and forkhead box class O 
(FOXO)3a plus IκB kinase (IKK)-β or an empty vector (control) as indi-
cated. Total lysates of the transfected cells were prepared and sub-
jected to luc assays. (c, d) Total lysates of 293T cells were co-
transfected with ERE-luc, pRL-TK, ER-α (panel c) or ER-β (panel d), 
and FOXO1a plus IKK-β or an empty vector as indicated and subjected 
to luc assays. All cells were cultured in the presence of 17β-estradiol 
(E2). The relative reporter luc activity was normalized with pRL-TK. Data 
are expressed means and standard deviations from three repeated 
experiments, which were performed independently. *P < 0.05 between 
FOXO (FOXO3a or FOXO1a) minus IKK-β (lane 3) versus FOXO plus 
IKK-β (lane 4).Breast Cancer Research    Vol 10 No 1    Zou et al.
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Figure 4
FOXO3a regulates expression of ER target genes and CDK inhibitors, and induces apoptosis in MCF-7 FOXO3a regulates expression of ER target genes and CDK inhibitors, and induces apoptosis in MCF-7. (a) Ectopic expression of Forkhead box 
class O (FOXO)3a reduces the expression of some estrogen receptor (ER)-regulated genes and enhances the expression of cyclin-dependent 
kinase (CDK) inhibitors in MCF7-FO cells in the presence of 17β-estradiol (E2). Immunoblotting (IB) analyses for HA-FOXO3a, endogenous 
FOXO3a, p27Kip1, p21Cip1, p57Kip2, cyclin D1, cyclin E, cathepsin D, progesterone receptor (PgR), ER-α, and ER-β protein expression in MCF7-
FO33 and MCF7-FO41 cells (constitutively expressing FOXO3a) and in control (MCF-7 and MCF7-C5) cells were performed with specific antibod-
ies, as indicated. Equal loading was confirmed by the same IB analysis with antibodies against β-actin or β-tubulin. (b) MDA-MB-453 (MDA-453, 
ER-negative) cells were transfected with either FOXO3a or an empty pCDNA3.1 vector (control), as indicated. Total lysates of the transfected cells 
were prepared and subjected to SDS-PAGE followed by IB analysis with the indicated antibodies.
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Because FOXO3a can promote apoptosis by upregulating
FasL expression [18-20,28,31], we also examined whether
FasL or Fas receptor (FasR) was induced by over-expression
of FOXO3a in MCF7-FO. However, no differences in expres-
sion of FasL or FasR were observed (data not shown), sug-
gesting that the FasR/FasL signaling pathway may not be
involved in FOXO-mediated apoptosis in MCF7-FO cells.
FOXO3a represses proliferation of MCF-7 cells in vitro
The MCF-7 cell line expresses ER-α and ER-β, and its prolifer-
ation requires estrogen stimulation. Hence, we sought to
examine the effect of FOXO3a on the proliferation of MCF-7
cells in the absence or presence of E2. Direct cell counts
showed that over-expression of FOXO3a significantly sup-
pressed the proliferation of MCF7-FO cells in culture, both
with and without E2. In the absence of E2 the average growth
rate of MCF7-FO10, MCF7-FO33, and MCF7-FO41 cells
was 38% (± 5%) less than that of the control MCF7-C4,
MCF7-C5, and MCF7-C12 cells (P = 0.002; Figure 5a). In the
presence of E2 the average growth rate of these three MCF7-
FO cell lines was reduced by 47% (± 11%; P = 0.008; Figure
5b). These findings indicate that proliferation of human estro-
gen-dependent breast cancer cells is suppressed by the con-
stitutive expression of FOXO3a.
FOXO3a suppresses E2-dependent tumor growth of 
MCF-7 in vivo
The antiproliferative effect of FOXO3a on MCF-7 in vitro
raised the possibility that constitutive expression of FOXO3a
might suppress tumor growth in vivo. Because MCF-7 is an
E2-dependent breast tumor cell line, no breast tumors were
detected when mice were not given E2 (data not shown).
When the control MCF7-C pooled cell lines were injected into
the mammary fat pads of female athymic mice given supple-
mental E2, breast tumors appeared in approximately 2 weeks
(Figure 6). Injection of the MCF7-FO pooled cell lines pro-
duced small tumors within about 2 weeks, but those tumors
did not grow thereafter (Figure 6). Overall, after 5 weeks the
average tumor growth of MCF7-FO pooled cells was 87% (±
21%) less than that of the control cell lines (P < 0.001) in the
presence of E2. These results indicate that constitutive
expression of FOXO3a in estrogen-dependent breast cancer
cells significantly suppresses E2-dependent tumor growth in
vivo in this orthotopic mouse model of breast cancer.
FOXO3a reduces the expression of certain ER-regulated 
genes and increases the expression of CDK inhibitors in 
MCF7-FO breast tumors
We then examined whether FOXO3a could regulate ER-medi-
ated signaling molecules and CDK inhibitors in MCF7-FO in
vivo. Immunohistochemical staining of the xenograft tumor
sections showed that FOXO3a had repressed the expression
of the ER target genes pS2, complement C3, cathepsin-D,
and PgR (Figure 7a), and upregulated the expression of
p21Cip1, p27Kip1, and p57Kip2 in tumors derived from
MCF7-FO cells relative to tumors derived from control MCF7-
C cells (Figure 7b). In accordance with our previous immuno-
blotting findings (Figure 4a), the expression levels of ER-α and
ER-β were largely unchanged between MCF7-C and MCF7-
FO tumor specimens. We also used immunoblotting of total
cell lysates to confirm the upregulation of p21Cip1, p27Kip1
and p57Kip2, and the downregulation of cyclin D1 in MCF7-
Figure 5
Ectopic expression of FOXO3a in estrogen-dependent breast cancer cells suppresses cell proliferation in cell culture Ectopic expression of FOXO3a in estrogen-dependent breast cancer cells suppresses cell proliferation in cell culture. (a) Growth of forkhead box 
class O (FOXO)3a over-expressing MCF7-FO (MCF7-FO10, MCF7-FO33, and MCF7-FO41) cells and control (MCF7-C4, MCF7-C5, and MCF7-
C12) cells in the absence of 17β-estradiol (E2) was determined by counting trypan-blue stained cells with a hemocytometer. Growth curves are the 
means of the three MCF7-FO cell lines (MCF7-FO10, MCF7-FO33, and MCF7-FO41) and the three control cell lines (MCF7-C4, MCF7-C5, and 
MCF7-C12); error bars indicate standard deviation from three experiments. (b) Growth of the same sets of cells in the presence of E2 (1 nmol/l). 
Growth curves are the means of the three MCF7-FO cell lines (designated MCF7-FO average) and the three control cell lines (designated MCF7-C 
average); error bars indicate standard deviaton from three experiments. *P < 0.05 between control MCF7-C group versus MCF7-FO group.Breast Cancer Research    Vol 10 No 1    Zou et al.
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FO tumors relative to MCF7-C tumors (Figure 7c). Similarly,
the expression of ER-α and ER-β proteins in total cell lysate
was no different in the MCF7-FO and MCF7-C tumor samples,
supporting the notion that FOXO3a may inhibit ER-mediated
signaling pathways through a nontranscriptional mechanism in
vivo. Collectively, these findings suggest that FOXO3a upreg-
ulates the expression of p21Cip1, p27Kip1 and p57Kip2, and
inhibits ER-mediated signaling in MCF-7; these effects may
lead to growth suppression in MCF7-FO tumor cells in vivo.
Taken together, these findings suggest that FOXO3a may
suppress tumor growth through inhibition of ER function or cell
growth control in estrogen-dependent breast cancer in vivo.
ER-α and ER-β bind to the unique domains of FOXO3a 
and FOXO3a downregulates FOXM1
To elucidate the candidate sites on FOXO3a by which
FOXO3a interacts with ER-α and ER-β to regulate their func-
tions, we examined the binding between FOXO3a and ER-α
or ER-β by using standard Glutathione-S-transferase (GST)
pull-down assays. The results showed that the amino-terminal
domain (amino acids 1 to 300) of FOXO3a binds to ER-α
whereas the carboxyl-terminal domain (amino acids 301 to
673) of FOXO3a binds to ER-β primarily (Figure 8a).
Because it was recently shown that FOXO3a can interact with
forkhead box m1 (FOXM1) on ER-α promoter and regulate
ER-α expression [36,37], we sought to determine whether
over-expression of FOXO3a could affect FOXM1 expression.
Our results showed that the level of FOXM1 protein was
downregulated in FOXO3a-over-expressing MCF-7 cell lines
(MCF7-FO41 and MCF7-FO10) as compared with that in the
control MCF7-C cells (MCF-7 wild-type and MCF7-C12; Fig-
ure 8b). These results are consistent with those previous find-
ings [36,37] suggesting that FOXO3a may repress ER-α
activity through an alternative mechanism by which FOXO3a
downregulates FOXM1 expression.
Silencing endogenous FOXO3a in MCF-7 cells promoted 
tumorigenesis in vivo
To further confirm the regulatory role played by endogenous
FOXO3a in suppressing tumor development and growth in the
orthotopic breast tumor mouse model, we generated MCF7-
d8_pa cells (pooled clones of MCF-7 FOXO3a knockdown
derivatives) by using retroviruses expressing short hairpin
RNA against human FOXO3a (Figure 8c). After injection of
MCF7-d8_pa or MCF-7 wild-type (control) cells (2 × 106
cells/mouse) into the mammary fat pads of female athymic
mice not given supplemental E2, the tumor growth rates of
these cells were determined. Our results showed that silenc-
ing of FOXO3a indeed promoted tumor growth or tumorigen-
esis of MCF7-d8_pa cells in female athymic mice not given
supplemental E2, whereas wild-type MCF-7 cells could not
grow tumors in athymic mice in the absence of E2 (Figure 8d).
Collectively, these results unambiguously confirm the tumor
suppression role of FOXO3a in MCF7 cells and suggest a role
for FOXO3a in preventing hormone-independent growth of
MCF7 cells in vivo.
Discussion
Here, we investigated the functional role of FOXO3a in estro-
gen-dependent breast cancer and showed that constitutive
expression of FOXO3a in MCF-7 suppressed proliferation in
vitro and estrogen-dependent breast tumor development in
vivo in an orthotopic breast cancer model. Strikingly, silencing
endogenous FOXO3a converted nontumorigenic, estrogen-
dependent MCF-7 cells into tumorigenic estrogen-independ-
ent cells, supporting the concept that FOXO3a plays a critical
tumor suppression role in estrogen-dependent breast cancer.
These results are consistent with recent findings that cancers
develop in mice that lack FOXO genes [38,39], indicating that
the FOXO molecules are bona fide tumor suppressors in
mammals. Reasoning that these findings might be extended to
the identification of agents (such as small molecules) that can
activate FOXO3a for development as a new tumor suppres-
sive therapeutic modality in breast cancer, we studied the
mechanisms by which FOXO3a suppressed the proliferation
and tumorigenicity of MCF-7.
p27Kip1 is known to be a transcriptional target of FOXO fac-
tors [18-20], and Smad-FOXO complexes can induce
p21Cip1 expression [40]. Interestingly, we found that
Figure 6
Ectopic expression of FOXO3a in estrogen-dependent breast cancer  cells suppresses breast tumor development in vivo Ectopic expression of FOXO3a in estrogen-dependent breast cancer 
cells suppresses breast tumor development in vivo. Forkhead box class 
O (FOXO)3a suppresses estrogen receptor (ER)-positive breast tumor 
development in a mouse model of breast cancer. The MCF7-FO pooled 
cell lines and the control MCF7-C pooled cell lines were injected (2 × 
106 cells/mouse) into the mammary fat pads of female athymic mice 
given supplementary 17β-estradiol (E2), as described in Materials and 
methods. Growth curves of tumor size are the means of the MCF7-FO 
pooled cell lines (designated MCF7-FO) and the control MCF7-C 
pooled cell lines (designated MCF7-C); error bars indicate standard 
deviation from three experiments. *P < 0.05 between control MCF7-C 
group versus MCF7-FO group.Available online http://breast-cancer-research.com/content/10/1/R21
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Figure 7
FOXO3a decreases expression of ER-regulated genes and increases CDK inhibitors in MCF7-FO breast tumors FOXO3a decreases expression of ER-regulated genes and increases CDK inhibitors in MCF7-FO breast tumors. (a) At 35 days after tumor cell 
implantation, breast tumors derived from female athymic mice bearing MCF7-FO or MCF7-C (control) tumors were resected, fixed, sectioned, and 
placed on slides. Five independent tumors (each from a different mouse) were tested in each mouse group. Tumor specimens were subjected to 
immunohistochemical (IHC) staining with antibodies specific to forkhead box class O (FOXO)3a, hemagglutinin (HA)-tag, pS2, complement C3, 
cathepsin (Cath)-D, progesterone receptor (PgR), and cyclin D1. Slides were examined at 40× magnification with a microscope. Numbers of posi-
tively staining cells in four random fields were counted in each tumor section, and representative fields are shown. Scale bars indicate 50 μm. *P < 
0.01 between control MCF7-C group versus MCF7-FO group. (b) At 35 days after tumor cell implantation, breast tumors derived from female ath-
ymic mice bearing MCF7-FO or MCF7-C (control) tumors were resected, fixed, sectioned, and placed on slides. Five independent tumors (each 
from a different mouse) were tested in each mouse group. Tumor specimens were subjected to IHC staining with antibodies to p21Cip1, p27Kip1, 
p57Kip2, estrogen receptor (ER)-α, and ER-β. Numbers of positively staining cells in four random fields were counted in each tumor section, and 
representative fields are shown. Scale bars indicate 50 μm. *P < 0.02 between control MCF7-C group versus MCF7-FO group. (c) Confirmation 
that FOXO3a enhances expression of cyclin-dependent kinase (CDK) inhibitors and reduces expression of cyclin D1 in tumors in immunoblotting (IB) 
analysis. Whole lysates of MCF7-FO or MCF7-C breast tumor specimens were subjected to IB analysis with antibodies to p21Cip1, p27Kip1, 
p57Kip2, cyclin D1, ER-α, ER-β, HA-tag and FOXO3a (positive controls), and β-actin (loading control).Breast Cancer Research    Vol 10 No 1    Zou et al.
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FOXO3a upregulated the expression of all three CDK inhibi-
tors tested (p21Cip1, p27Kip1, and p57Kip2; Figure 4a). This
finding is novel and important because FOXO3a has been
shown to regulate entry into and exit from mitosis [26], which
is critical in regulating cell proliferation or apoptosis in normal
and cancerous cells. These findings also confirm our observa-
tions that FOXO3a inhibited the growth of estrogen-depend-
ent breast cancer cells both in culture and in an orthotopic
mouse model of breast cancer, suggesting that FOXO3a is
involved in suppressing tumor growth or tumorigenesis and
ER-mediated signaling in ER-positive breast tumors in vivo.
Downregulation of cyclin D was previously reported to be
involved in FOXO-induced cell cycle inhibition in some cancer
Figure 8
ER-α and ER-β bind to the amino-terminal and carboxyl-terminal domains of FOXO3a, respectively ER-α and ER-β bind to the amino-terminal and carboxyl-terminal domains of FOXO3a, respectively. (a) Glutathione-S-transferase (GST) – pull down 
in vitro assays. Whole cell lysates from 293T cells were incubated with the GST-forkhead box class O (FOXO)3a (GST-FO [amino acids 1 to 300] 
and GST-FO [amino acids 301 to 673]) fusion proteins as indicated and GST alone (negative control), and analyzed by SDS-PAGE and immunob-
lotting with an antibody (Ab) against estrogen receptor (ER)-α or ER-β (upper panels) and an anti-GST Ab (lower panel) as protein controls. (b) 
FOXO3a downregulates FOXM1. Immunoblotting (IB) analyses for endogenous FOXO3a, forkhead box M1 (FOXM1), and β-actin (loading control) 
protein expression in MCF7-FO10 and MCF7-FO41 cells (constitutively expressing FOXO3a) and in control (MCF-7 wt and MCF7-C12) cells were 
performed with specific antibodies antibodies as indicated. (c) MCF7-d8_pa cells (pooled clones of MCF-7 FOXO3a-knockdown derivatives) were 
established with retroviruses expressing small hairpin RNA against human FOXO3a. The expression levels of FOXO3a and p27Kip1 in MCF-7 wild-
type (wt) and MCF7-d8_pa cells were determined by IB with specific Abs against FOXO3a or p27Kip1 or β-actin (loading control). (d) Silencing 
endogenous FOXO3a in MCF-7 cells promoted tumorigenesis in vivo. The tumor growth rates of control group MCF-7 wt and knockdown group 
MCF7-d8-pa were determined after injection of cells (2 × 106cells/mouse) as indicated into the mammary fat pads of female athymic mice not given 
supplemental 17β-estradiol (E2; indicated as – E2). Data are expressed as means and standard deviations from two experiments with five mice in 
each group. *P < 0.01 between MCF7-d8-pa group versus control MCF-7 wt group.Available online http://breast-cancer-research.com/content/10/1/R21
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cell types such as colon carcinoma cell lines [27]. Because it
has been shown that D-type cyclins are regulated by estrogen
and ER, and play important roles in controlling cell growth
[41], we compared the expression of cyclins D1, D2, and D3
between MCF7-FO cells and the control MCF7-C cells. In
agreement with their findings, we found that the expression of
cyclin D1 was reduced in MCF7-FO cells as compared with
that in control MCF7-C cells (Figure 4a). However, we could
not detect any significant difference in the expression of cyc-
lins D2 and D3 between MCF7-FO cells and the control MCF7-
C cells (data not shown), suggesting that downregulation of
cyclins D2 and D3 may not be involved in FOXO3a-induced
growth arrest in MCF-7 breast cancer cells. In addition, we
found that the expression of cyclin E is not significantly altered
in these MCF7-FO cells either (Figure 4a). These results
suggest that cell growth arrest induced by FOXO3a may be
primarily through upregulation of key CDK inhibitors instead of
downregulation of cyclins in MCF7-FO cells.
It was previously shown that ER-α interacts with FOXO3a
(FKHRL1) in a ligand-dependent manner, and the ligand-
dependent ER-α-FKHR interaction can be inhibited by
tamoxifen [42]. However, those data suggest that FKHR-TM
activates ER-α-mediated transcriptional activity. In contrast,
another report [43] demonstrated that FKHR interacts with
ER-α and represses ER-α-mediated transactivation. Both
studies [42,43] were mainly based on transient co-transfec-
tion reporter experiments. The differences between the two
studies can be attributed to the different vectors or
approaches used. Because the regulation of ER-α plays a piv-
otal role in breast cancer and these two reports appear to be
contradictory in their findings, further investigation of the role
of FOXO in regulating ER function in vivo is certainly justified
and necessary.
Using orthotopic breast cancer xenograft mouse models, for
the first time we clearly showed that over-expression of
FOXO3a in MCF-7 cells suppressed their ER-dependent
tumorigenesis and growth in vivo. Our results support that
FOXO3a represses the transcriptional activity of ER-α, as was
described by Zhao and coworkers [43]. Both studies show
that FOXO represses the transcriptional activity of ER-α in an
interaction that is dependent on E2 (an agonist). In addition,
we show that FOXO3a also suppresses the transcriptional
activity of ER-β. This is important in breast cancer cells
because, under physiological conditions, ER appears to be
positively regulated by estrogen in breast cancer cells. How-
ever, when FOXO3a is active, FOXO3a can antagonize the
estrogen-dependent functions of ER-α and ER-β, resulting in
suppression of ER-mediated tumor growth and development.
We further investigated the role played by FOXO3a in inhibit-
ing ER-mediated signaling and growth of the estrogen-
dependent breast cancer cells. Our finding that silencing
FOXO3a in MCF-7 promoted tumorigenesis and tumor
growth in an E2-independent manner in vivo (Figure 8d) fur-
ther supports the notion that FOXO3a plays a critical role in
repressing the ER-mediated survival pathway in vivo. One
plausible mechanism of this effect is that ER becomes
constitutively active in the absence of estrogen (such as the
development of hormone-refractory disease) when MCF-7
cells are lacking FOXO3a, an ER co-repressor. The second
possible mechanism of this effect is that silencing of FOXO3a
might induce certain receptor tyrosine kinases, which in turn
activate ER activity in MCF-7 cells in an estrogen-independent
manner. The third possible mechanism of this effect could be
that other factors (such as cytokines or chemokines) might be
upregulated in MCF-7 cells that lack FOXO3a through
autocrine regulation and contribute to this hormone-independ-
ent growth effect. However, we have no mechanistic data to
prove the possible mechanism of this effect at present. Further
elucidation of the molecular mechanism that underlies this
effect will lead to better understanding of the role of FOXO3a
in preventing hormone-independent growth of MCF7 cells in
vivo.
Notably, we also demonstrated a direct physical interaction
between FOXO3a and ER-α or ER-β and suppression of ER-
α and ER-β transactivation activities by FOXO3a in vitro. Tran-
sient over-expression of FOXO3a has been shown to lead to
increases in ER-α expression and ER-α promoter activity in a
reporter assay in ER-α-positive NF639 cells [44]. However,
we found that the expression of ER-α and ER-β proteins was
not significantly affected by the ectopic expression of
FOXO3a in all three variants (MCF7-FO) of ER-α-positive and
ER-β-positive MCF-7 cells. One possible explanation for this
difference is that FOXO3a can function on the one hand as a
co-repressor, one that is associated with ER-α and ER-β pro-
teins and inhibits their transactivating activities; and on the
other hand as a transcription factor that binds the promoter of
ER-α and induces transcription of ER-α as a feedback mech-
anism in some situations. Alternatively, the observed
difference could be due to differences in the expression meth-
ods or the cell lines used.
Because many estrogen-dependent breast cancer cells
express both ER-α and ER-β, one plausible meaning of this
observation is that FOXO may interact with ER-α and ER-β
simultaneously at different FOXO domains, resulting in inhibi-
tion of both ER-α and ER-β function in breast cancer cells and
suppression of ER-mediated tumor growth and development.
In general, ER-α and ER-β consist of six functional domains.
The structurally distinct amino terminal A/B domains (17%
amino acid identity) contain a ligand-independent transactiva-
tion function (AF1). The near identical central C region is the
DNA-binding domain. The flexible hinge, or D, domain contains
a nuclear localization signal and links the C domain to the mul-
tifunctional carboxyl-terminal (E/F) domain, which exhibits
56% amino-acid homology between ER-α and ER-β. E/F is
involved in ligand binding, dimerization, and ligand-dependentBreast Cancer Research    Vol 10 No 1    Zou et al.
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transactivation functions (AF2). Thus, the second possible sig-
nificance of this phenomenon is that ER-α and ER-β may use
distinct functional domains to interact with FOXO at different
domains so that ER-α and ER-β may not compete for the bind-
ing site of FOXO. Moreover, it has been shown that ER-α and
ERβ can form heterodimers on DNA, and they interacted with
ERE and E2 in a manner similar to that observed with the ER
homodimers [45]. The third possible implication of this finding
is that ER-α and ER-β heterodimers may interact with FOXO
at different domains to form a large complex that could not
bind to ERE on DNA, and thereby ER-α/ER-β are not
functional.
Finally, our findings provide a mechanistic basis for FOXO3a-
mediated tumor suppression in ER-positive breast cancer
cells. FOXO3a inhibited ER-mediated signaling through a
nongenomic mechanism and upregulated the expression of
three CDK inhibitors that could result in suppression of tumor
growth and tumorigenesis in estrogen-dependent breast can-
cer cells in vivo. Although our results were generated using
MCF-7 variants and mouse models, the in vivo data in partic-
ular may have important clinical implications for treating or pre-
venting the development of resistance to endocrine therapy.
For instance, the development of resistance to antiestrogen
therapy remains a clinically important problem. However, a
major limitation in alternative approaches to treating or pre-
venting antiestrogen resistance is that we lack knowledge of
the precise signaling mechanisms that underlie the regulation
of ER function and development of ER-unresponsiveness in
ER-positive breast cancer cells in vivo. Further investigation of
FOXO factors in inhibition of ER function and signaling may
contribute new insights into this problem. Understanding the
molecular basis of FOXO3a-induced suppression of cell
growth and tumor development could also provide opportuni-
ties to develop innovative anticancer therapeutic modalities,
such as small molecules that can activate FOXO3a, thereby
potentially suppressing the growth of breast tumors and pos-
sibly preventing recurrence after therapy.
Conclusion
We suggest that FOXO3a plays a critical role in suppressing
estrogen-dependent breast cancer cell growth and tumorigen-
esis in vivo. Our data further support that agents such as small
molecules that activate FOXO3a may be novel therapeutics
for inhibition and prevention of tumor proliferation and devel-
opment in breast cancer.
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